NHS Health Check

NHS Health Check
Name	NHS Health Check
Established	2009
Country	United Kingdom
Administered by	National Health Service
Type	Preventive health screening programme
Target population	Adults aged 40–74 in England

NHS Health Check The NHS Health Check is a preventive screening programme introduced in England in 2009 to assess cardiovascular and metabolic risk among adults aged 40–74. It operates within the National Health Service (England) framework and interfaces with local authorities, clinical commissioning groups, and primary care networks including NHS England. The programme aligns with public health initiatives championed by figures and institutions such as Dame Sally Davies, Public Health England, and municipal health departments like London Borough of Tower Hamlets.

Overview

The programme was launched following recommendations from advisory bodies including the National Institute for Health and Care Excellence and debates in the House of Commons and House of Lords about population screening policy. It targets asymptomatic individuals to identify risk factors for conditions represented in datasets like the Clinical Practice Research Datalink and registries maintained by NHS Digital. Delivery models have ranged from general practice-based checks to community outreach led by organizations such as Age UK and charities like British Heart Foundation. Evaluations have involved collaborations with universities including University of Oxford, King's College London, and University College London.

Purpose and Eligibility

The stated purpose is to reduce incidence of cardiovascular disease events by identifying elevated risk of coronary heart disease, stroke, type 2 diabetes mellitus, and associated risk factors among eligible adults. Eligibility criteria apply to adults aged 40–74 without pre-existing diagnoses recorded in NHS systems such as Hospital Episode Statistics or primary care registers like the Quality and Outcomes Framework. Exclusions include people with established conditions recorded under Read codes or SNOMED CT entries for diseases such as established diabetes mellitus or chronic kidney disease. Local authorities and primary care trusts implement invitations and recall using patient lists generated from systems including SystmOne and EMIS Web.

Screening Components and Process

The screening pathway typically includes measurement of blood pressure using devices produced by manufacturers used in NHS settings, lipid profile testing for total cholesterol and HDL, calculation of body mass index, smoking status assessment, and alcohol consumption screening often via the AUDIT-C tool. A venous or capillary sample analyzed by laboratories affiliated with trusts such as Guy's and St Thomas' NHS Foundation Trust yields lipid results, while risk scoring uses algorithms like QRISK2 or QRISK3. The process often employs electronic templates integrated into electronic health record systems and is delivered during an appointment lasting approximately 20–30 minutes in clinics, GP surgeries, community pharmacies affiliated with chains like Boots Pharmacy, or mobile units deployed by local authorities.

Risk Assessment and Follow-up

Risk estimation commonly uses 10-year cardiovascular risk scores generated by QRISK calculators with inputs from patient demographics and clinical measures. Results guide interventions aligned with NICE guideline PH56 recommendations including lifestyle advice, referral to smoking cessation services provided by local providers, referral to weight management programmes such as those run by WeightWatchers pilots, and consideration of pharmacotherapy like statins following shared decision-making with clinicians from bodies like the Royal College of General Practitioners. High-risk individuals may be referred into secondary prevention pathways overseen by hospitals such as Royal Brompton Hospital or specialist clinics in NHS Trusts.

Effectiveness and Outcomes

Assessments of population impact have been mixed, with cohort analyses and randomised evaluations by research groups at Imperial College London and University of Cambridge reporting modest changes in risk factor detection, pharmacological treatment uptake, and population-level risk. Health economic modelling referencing cost-effectiveness frameworks used by NICE and outcomes reported to Public Health England indicate variable incremental benefits depending on uptake, adherence to interventions, and integration with secondary prevention programmes. Surveillance of outcomes uses data linkage across Office for National Statistics mortality records and primary care datasets.

Delivery, Providers, and Settings

Delivery has involved multidisciplinary teams including practice nurses, healthcare assistants, pharmacists, and community health workers affiliated with primary care networks and trusts such as Cambridge University Hospitals NHS Foundation Trust. Settings include general practice surgeries, community pharmacies, workplace health schemes in corporations like British Airways pilots' programmes, and outreach in faith-based venues coordinated with partners such as FaithAction. Commissioning and oversight fall to local authorities' public health departments, often contracting third-party providers including social enterprises and private providers regulated under frameworks established by Care Quality Commission.

Controversies and Criticisms

Critiques have centred on clinical effectiveness, opportunity cost, and resource allocation debated in forums such as The King's Fund and reported in outlets like The BMJ and The Lancet. Concerns include false reassurance, overdiagnosis, low uptake in deprived populations identified through indices like the Index of Multiple Deprivation, and inconsistent implementation across local authorities leading to health inequalities. Debates have involved professional bodies including British Medical Association and patient advocacy groups, with legal and policy scrutiny referenced during parliamentary inquiries and reviews by National Audit Office and academic critiques from institutes such as Nuffield Trust.